Anika Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 total revenue increased 10% to $30.6 million from $27.8 million, with commercial channel revenue up 17% to a record $14 million and OEM channel revenue up 5% to $16.6 million.
- For the first 9 months, commercial channel revenue grew 15% and OEM channel revenue grew 11%.
- International OA pain management revenue increased 19% in the quarter, and total Regenerative Solutions revenue increased 12%; Integrity revenue grew more than 30% year over year and 37% year to date.
- Gross margin was 62%, compared with 56% a year ago and 65% in the 2nd quarter; management attributed the year-over-year improvement to manufacturing execution and the sequential decline primarily to product mix, including the reintroduction of HyalMatrix.
- Total operating expenses were $19.5 million, up 4%; research and development expense was $7.9 million, while selling, general, and administrative expense declined to $11.7 million, with total G&A excluding stock-based compensation down 19% compared with last year.
- GAAP operating loss narrowed to $0.7 million from $3.2 million; GAAP loss from continuing operations was $0.3 million, or $0.02 per share, compared with a loss of $3.2 million, or $0.22 per diluted share.
- Adjusted net income from continuing operations was $3.9 million, or $0.29 per diluted share, and adjusted EBITDA was $5.1 million compared with $0.9 million last year and $7.1 million in the 2nd quarter.
- The company generated $8.4 million of operating cash in the quarter and invested $1.7 million in capital expenditures; cash and cash equivalents were $45 million at September-end, compared with $38.4 million at the end of June.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to Anika's third quarter earnings conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require media assistance, please press star 0 for the operator. This call is being recorded on Friday, November 6, 2026. I will now turn the call over to Matt Hall, Executive Director of Corporate Development and Investor Relations.
Please proceed. Good morning. Thank you for joining us for Anika's third quarter 2026 earnings call.
I am Matt Hall, Anika's Executive Director of Corporate Development and Investor Relations. Our earnings press release was issued earlier this morning and is available on our investor relations website, as are our supplementary PowerPoint slides that will be used for discussion today. With me on the call are Steve Griffin, President and Chief Executive Officer, and Ian McLeod, Senior Vice President, Chief Accounting Officer, and Treasurer. They will present our third quarter 2026 financial results and business highlights. Please take a moment and open the slide presentation and refer to slide two. Before we begin, please understand that certain statements made during the call today constitute forward-looking statements as defined in the Securities Exchange Act of 1934. These statements are based on our current beliefs and expectations and are subject to certain risks and uncertainties.
The company's actual results could differ materially from any anticipated future results, performance, or achievements. We make no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today. Please also see our most recent SEC filings for more information about risk factors that could affect our performance. In addition, during the call, we may refer to several adjusted or non-GAAP financial measures, which may include adjusted gross margin, adjusted EBITDA, adjusted net income from continuing operations, and adjusted earnings per share from continuing operations, which are used in addition to results presented in accordance with GAAP financial measures. We believe that non-GAAP measures provide an additional way of viewing aspects of our operations and performance, but when considered with GAAP financial measures and the reconciliation of GAAP measures, they provide an even more complete understanding of our business.
A reconciliation of these adjusted non-GAAP financial results to the most comparable GAAP measurements are available at the end of the presentation slide deck and our third quarter 2026 press release. With that, I will turn the call over to Steve to discuss the quarter and our progress.
Steve? Good morning, everyone, and thank you for joining us.
Our third quarter performance marked another positive step in building a stronger, more profitable Anika. Revenue grew 10% with growth in both our commercial and OEM channels. We improved gross margin year-over-year, expanded adoption of Integrity, completed key manufacturing and pipeline milestones, and strengthened a long-term partnership that will contribute to future growth. These results also reinforce the strategic focus we have built around our core hyaluronic acid platform and the opportunities it creates across our business. At the start of this year, we established revenue growth as our most important goal for 2026. Through the first nine months, commercial channel revenue is up 15% and OEM channel revenue is up 11%.
That progress reflects the increased focus on our core HA portfolio and execution against the three priorities we laid out in February: accelerating sustainable revenue growth, driving operational excellence across the organization, and advancing our hyaluronic acid-based innovation pipeline. I'll provide updates on each of those priorities, including where we are making progress and where our future work is focused. Our first priority remains accelerating sustainable revenue growth. Commercial channel revenue increased 17% to $14 million in the third quarter, another record. We continue to see demand across our international OA pain management business and our regenerative portfolio, with Cingal, Monovisc, and Integrity contributing to that performance. International OA pain management revenue grew 19% in the quarter, supported by sustained demand for Cingal and Monovisc. These are established products with an important role in our portfolio.
Last quarter, I talked about the benefits of bringing greater focus to the international business and aligning our organization and distributors around our core HA products. The third quarter results give us further reason to continue that focus. We are investing more in where we see opportunities to grow international sales, including adding new frontline commercial team members in a cost-neutral way. Within regenerative solutions, total revenue increased 12%. Integrity revenue grew more than 30% year-over-year and increased sequentially, bringing year-to-date growth to 37%. Integrity has generated $7.5 million in revenue over the trailing 12 months as we enter the fourth quarter, traditionally the strongest seasonal quarter for elective surgery. The larger implant sizes introduced in the fourth quarter of 2025 and the first quarter of this year have been an important part of that growth.
They have expanded use of Integrity into other tendon applications, including foot and ankle and knee. That matters because the opportunity for the platform extends beyond a single anatomy. Surgeons need the sizes and the instrumentation to use the implant across a broader range of tendon repair procedures. In September, we launched second-generation Integrity instrumentation that provides an alternative insertion and deployment option to address differences in surgeon preference. This is a practical enhancement to the platform, giving surgeons another way to work with the implant as adoption expands. We remain encouraged by Integrity's sequential and year-over-year revenue growth. Market-wide seasonality was more pronounced than usual in the summer months. As has been reported by hospital operators and other orthopedic companies, elective surgical procedures in the U.S. were slower during the third quarter.
Our updated commercial channel outlook continues to reflect growth in the fourth quarter, but it is not expected to make up for the softness seen over the summer months. Ian will walk through the updated ranges in his prepared remarks. Turning to the OEM channel, revenue increased 5% in the quarter and 11% through the first nine months, supported by continued execution with J&J and our non-orthopedic products. Our U.S. Orthovisc and Monovisc relationship remain an important part of the business. As we discussed last quarter, customer ordering patterns can create variability from one quarter to the next, so we look at performance over a longer period as well as the individual quarter. Last quarter, I also highlighted the opportunity to improve growth and profitability across our broader OEM portfolio. We have several longstanding relationships and longstanding products that can contribute meaningfully to revenue and cash flow.
This quarter's update includes tangible progress on that work. This month, we entered into a new 10-year distribution agreement with our existing Hyvisc partner, Boehringer Ingelheim. The agreement provides higher transfer pricing, a royalty on end market sales, higher contractual minimum purchases, and upfront and milestone payments. In total, we expect to receive $8 million in payments, with a $4 million upfront payment expected in the first quarter of 2027, and the remaining $4 million tied to commercial volumes. Boehringer has been a trusted partner for more than 20 years, and we expect to continue that relationship through the coming decade under our new agreement. Together with our other long-term U.S. agreements, these partnerships solidify important revenue streams and illustrate the growing demand for our products.
Hyalomatrix, our HYAFF wound product, is now included within the OEM channel, and we shipped the first commercial units to a new OEM distributor during the third quarter. Reintroducing Hyalomatrix gives us another way to put our existing technology and manufacturing capabilities to work. Our second priority is strengthening operational discipline and execution. Gross margin was 62% in the third quarter compared with 56% a year ago. That improvement reflects the work underway to make our manufacturing operations more productive and better able to support demand. We have made progress, but we continue to see opportunities to increase output and improve the way that we run the business. Last quarter, I discussed the capacity expansion on our Monovisc and Cingal line and upgrades to our Orthovisc and non-orthopedic line. Those projects address constraints in our operation.
We have continued that work with stronger production planning, process improvements, and greater sourcing flexibility. Recent progress includes FDA approval of a new aseptic manufacturing process and validation of a second cross-link filler. These are specific improvements that expand our capacity to meet growing demand. Unit volumes on our cross-link line are now more than 50% higher than 2022 levels as we meet demand above our forecasts. We see further opportunity to expand output. As demand continues to grow, we are increasing production and building safety stock to support the business. The objective is to meet customer needs while improving productivity and gross margin over time. Our lean transformation is about improving how we do the work every day, simplifying processes, reducing waste, and addressing constraints where they occur. As I said last quarter, the teams closest to the work have an important role in identifying and solving those problems.
This approach remains central to how we improve manufacturing execution and continue building a more efficient organization. The quarter also illustrates why margin improvement will not necessarily be a straight line. Gross margin was lower than the 65% we reported in the second quarter, primarily because of the mix impact of products, including the reintroduction of Hyalomatrix, which does not yet include future royalty revenue from product sales. We expect the product's margin contribution to improve as those benefits develop. Turning to our third priority, advancing our HA-based innovation pipeline, our approach remains focused on applications where our experience with hyaluronic acid and HYAFF can address unmet needs in OA pain management and regenerative solutions. We're investing in the clinical, manufacturing, and quality work needed to move these programs forward. Starting with Cingal, there are two important deliverables to be completed before we file the NDA.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
